PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
153.33%
Revenue growth exceeding 1.5x AXSM's 44.67%. David Dodd would verify if faster growth reflects superior business model.
-27.15%
Cost reduction while AXSM shows 19.08% growth. Joel Greenblatt would examine competitive advantage.
73.30%
Gross profit growth exceeding 1.5x AXSM's 47.97%. David Dodd would verify competitive advantages.
89.46%
Margin expansion exceeding 1.5x AXSM's 2.28%. David Dodd would verify competitive advantages.
8.30%
R&D growth while AXSM reduces spending. John Neff would investigate strategic advantage.
28.80%
G&A growth less than half of AXSM's 139.06%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.70%
Operating expenses growth less than half of AXSM's 35.59%. David Dodd would verify sustainability.
14.70%
Total costs growth less than half of AXSM's 35.06%. David Dodd would verify sustainability.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-27.15%
D&A reduction while AXSM shows 2.71% growth. Joel Greenblatt would examine efficiency.
-16.20%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
54.13%
EBITDA margin growth exceeding 1.5x AXSM's 8.33%. David Dodd would verify competitive advantages.
-15.23%
Both companies show declining income. Martin Whitman would check industry conditions.
54.52%
Operating margin growth exceeding 1.5x AXSM's 9.29%. David Dodd would verify competitive advantages.
98.15%
Other expenses growth above 1.5x AXSM's 45.19%. Michael Burry would check for concerning trends.
-12.38%
Both companies show declining income. Martin Whitman would check industry conditions.
55.64%
Pre-tax margin growth exceeding 1.5x AXSM's 5.56%. David Dodd would verify competitive advantages.
-98.15%
Tax expense reduction while AXSM shows 129.07% growth. Joel Greenblatt would examine advantage.
-9.33%
Both companies show declining income. Martin Whitman would check industry conditions.
56.84%
Net margin growth exceeding 1.5x AXSM's 2.30%. David Dodd would verify competitive advantages.
-5.41%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-8.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
2.98%
Share count reduction below 50% of AXSM's 4.18%. Michael Burry would check for concerns.
2.03%
Diluted share reduction exceeding 1.5x AXSM's 4.18%. David Dodd would verify capital allocation.